TY - JOUR
T1 - Antibody-Functionalized Porous Silicon Nanoparticles for Vectorization of Hydrophobic Drugs
AU - Secret, Emilie
AU - Smith, Kevin
AU - Dubljevic, Valentina
AU - Moore, Eli
AU - MacArdle, Peter
AU - Delalat, Bahman
AU - Rogers, Mary-Louise
AU - Johns, Terrance
AU - Durand, Jean-Olivier
AU - Cunin, Frédérique
AU - Voelcker, Nicolas
PY - 2013/5
Y1 - 2013/5
N2 - We describe the preparation of biodegradable porous silicon nanoparticles (pSiNP) functionalized with cancer cell targeting antibodies and loaded with the hydrophobic anti-cancer drug camptothecin. Orientated immobilization of the antibody on the pSiNP is achieved using novel semicarbazide based bioconjugate chemistry. To demonstrate the generality of this targeting approach, the three antibodies MLR2, mAb528 and Rituximab are used, which target neuroblastoma, glioblastoma and B lymphoma cells, respectively. Successful targeting is demonstrated by means of flow cytometry and immunocytochemistry both with cell lines and primary cells. Cell viability assays after incubation with pSiNPs show selective killing of cells expressing the receptor corresponding to the antibody attached on the pSiNP. Mesoporous silicon nanoparticles that are able to specifically target and deliver hydrophobic anti-cancer drugs to cancer cells are developed. Porous silicon nanoparticles are functionalized with antibodies in a controlled way, in order to efficiently target cancer cells expressing the corresponding receptor. High targeting and killing efficiency is demonstrated in vitro on three types on cancer cells: neuroblastoma, glioblastoma and lymphoma cells.
AB - We describe the preparation of biodegradable porous silicon nanoparticles (pSiNP) functionalized with cancer cell targeting antibodies and loaded with the hydrophobic anti-cancer drug camptothecin. Orientated immobilization of the antibody on the pSiNP is achieved using novel semicarbazide based bioconjugate chemistry. To demonstrate the generality of this targeting approach, the three antibodies MLR2, mAb528 and Rituximab are used, which target neuroblastoma, glioblastoma and B lymphoma cells, respectively. Successful targeting is demonstrated by means of flow cytometry and immunocytochemistry both with cell lines and primary cells. Cell viability assays after incubation with pSiNPs show selective killing of cells expressing the receptor corresponding to the antibody attached on the pSiNP. Mesoporous silicon nanoparticles that are able to specifically target and deliver hydrophobic anti-cancer drugs to cancer cells are developed. Porous silicon nanoparticles are functionalized with antibodies in a controlled way, in order to efficiently target cancer cells expressing the corresponding receptor. High targeting and killing efficiency is demonstrated in vitro on three types on cancer cells: neuroblastoma, glioblastoma and lymphoma cells.
KW - Antibodies
KW - Cancer therapy
KW - Drug delivery
KW - Nanoparticles
KW - Porous silicon
KW - Vectorization
UR - http://onlinelibrary.wiley.com/doi/10.1002/adhm.201200335/pdf
UR - http://www.scopus.com/inward/record.url?scp=84879608162&partnerID=8YFLogxK
U2 - 10.1002/adhm.201200335
DO - 10.1002/adhm.201200335
M3 - Article
SN - 2192-2640
VL - 2
SP - 718
EP - 727
JO - Advanced Healthcare Materials
JF - Advanced Healthcare Materials
IS - 5
ER -